<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2020-4-746-751</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-1368</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL &amp; EXPERIMENTAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Ангиотензин-II как пусковой фактор развития ретинопатии недоношенных</article-title><trans-title-group xml:lang="en"><trans-title>Angiotensin-II as a Trigger Factor in the Development of Retinopathy of Prematurity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Катаргина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Katargina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заместитель директора по научной работе, начальник отдела патологии глаз у детей,</p><p>ул. Садовая-Черногрязская, 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>МD, Professor, head of the department of eye disease of children,</p><p>Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чеснокова</surname><given-names>Н. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Chesnokova</surname><given-names>N. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор биологических наук, профессор, руководитель отдела патофизиологии и биохимии,</p><p>ул. Садовая-Черногрязская, 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Doctor of biological sciences, Professor, head of the department of pathophysiology and biochemistry,</p><p>Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Безнос</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Beznos</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отдела патофизиологии и биохимии,</p><p>ул. Садовая-Черногрязская, 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>research officer of the department of pathophysiology and biochemistry,</p><p>Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, научный сотрудник отдела патологии глаз у детей,</p><p>ул. Садовая-Черногрязская, 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>PhD, research officer of the department of eye disease of children,</p><p>Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062</p></bio><email xlink:type="simple">natashamma@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Panova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант отдела патологии глаз у детей,</p><p>ул. Садовая-Черногрязская, 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>postgraduate of the department of eye disease of children,</p><p>Sadovaya-Chernogryazskaya str., 14/19, Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр глазных болезней им. Гельмгольца»&#13;
Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center for Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2020</year></pub-date><volume>17</volume><issue>4</issue><fpage>746</fpage><lpage>751</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Катаргина Л.А., Чеснокова Н.Б., Безнос О.В., Осипова Н.А., Панова А.Ю., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Катаргина Л.А., Чеснокова Н.Б., Безнос О.В., Осипова Н.А., Панова А.Ю.</copyright-holder><copyright-holder xml:lang="en">Katargina L.A., Chesnokova N.B., Beznos O.V., Osipova N.A., Panova A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/1368">https://www.ophthalmojournal.com/opht/article/view/1368</self-uri><abstract><p>Многофакторность патогенеза ретинопатии недоношенных (РН) делает актуальным поиск новых участников развития патологической неоваскуляризации. При этом в последние годы внимание ученых привлекает участие ренин-ангиотензиновой системы (РАС) в развитии вазопролиферативных заболеваний сетчатки.</p><sec><title>Цель</title><p>Цель: изучение роли АТ-II в патогенезе экспериментальной РН (ЭРН) на оригинальной модели заболевания.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. С целью воспроизведения ЭРН крысят породы Вистар (n = 15) вместе с родившей их самкой, начиная с первых суток после рождения, на 14 суток помещали в инкубатор, в котором каждые 12 часов концентрация кислорода менялась от 60 до 15 %. Затем крысят помещали в условия с нормальным содержанием кислорода (21 %). На протяжении эксперимента в помещении поддерживали постоянный температурный (+26 °С) и световой (12 часов день, 12 часов ночь) режим. Контрольную группу составили крысята (n = 12), находившиеся с момента рождения в условиях с нормальным содержанием кислорода (21 %). Партии крысят опытной (n = 5) и контрольной (n = 4) группы выводили из эксперимента на 7, 14 и 21 сутки. Всем крысятам проводили бинокулярную энуклеацию, после этого глазное яблоко вскрывали по лимбу, удаляли роговицу и хрусталик вместе с остатками персистирующей сосудистой сумки и гиалоидной артерии, выделяли сетчатку, в образцах которой измеряли содержание ангиотензина-II (АТ-II) с помощью набора для ИФА.</p></sec><sec><title>Результаты</title><p>Результаты. На 7-е сутки эксперимента уровень АТ-II в сетчатке крысят опытной группы составил 0,19 ± 0,02 пг/мг белка и был достоверно выше по сравнению с данным показателем в группе контроля (0,12 ± 0,01 пг/мг белка). На 14-е и 21-е сутки эксперимента уровень АТ-II не имел достоверных отличий между группами.</p></sec><sec><title>Заключение</title><p>Заключение. На 7-е сутки эксперимента, т.е. на сроке, соответствующем существованию аваскулярных зон сетчатки, в обеих исследуемых группах животных уровень АТ-II был достоверно выше по сравнению с группой контроля, что может свидетельствовать о патогенетической роли данного участника РАС в индукции патологической неоваскуляризации при ЭРН и о его возможной прогностической функции до манифестации заболевания, что имеет несомненное практическое значение. </p></sec></abstract><trans-abstract xml:lang="en"><p>The multifactorial nature of the retinopathy of prematurity (ROP) pathogenesis, makes the thorough study of the mechanism of pathological retinal neovascularization actual. However recently the attention of scientists has been attracted by the participation of renin-angiotensin system (RAS) in the development of retinal vasoproliferative diseases. Purpose: to study the role of AT-II in the pathogenesis of experimental ROP (EROP) in the original model of the disease. Material and methods. To reproduce EROP Wistar rats (n = 15) were exposed to the oxygen concentration varying from 60 to 15% every 12 hours for 14 days from the first day after birth followed by room air for 7 days. Throughout the experiment, the room maintained a constant temperature (+26 °C) and light regime (12 hours a day, 12 hours a night) modes. Control rats (n = 12) were born and kept under normal oxygen content (21 %). Batches of EROP (n = 5) and control (n = 4) rats were sacrificed on 7, 14 and 21 days. All rats underwent binocular enucleation, after which every eyeball was opened on the limb, the cornea and lens were removed with the remains of a persistent vascular bag and a hyaloid artery. Retinas were isolated, homogenized and stored at -20 °C. Angiotensin-II (AT-II) in homogenates was measured using the IFA kit. Results. On the 7th day of the experiment, the level of AT-II in the retina of the experimental group rats was 0.19 ± 0.02 pg/mg protein that was significantly higher than in controls (0.12 ± 0.01 pg/mg protein). On the 14th and 21st days concentrations of AT-II in EROP and control groups had no significant difference. Conclusion. On the 7th day of the experiment, i.e. at the period corresponding to the existence of avascular retinal zones in both groups concentration of AT-II in the retinas of rats with EROP was significantly higher than in controls. This fact indicate the role of this proangiogenic factor in the induction of pathological neovascularization in ROP. Possible prognostic function of this parameter during the period before ROP manifestation has undoubted practical significance.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ретинопатия недоношенных</kwd><kwd>эксперимент</kwd><kwd>крысиная модель</kwd><kwd>патогенез</kwd><kwd>ренин-ангиотензиновая система</kwd></kwd-group><kwd-group xml:lang="en"><kwd>retinopathy of prematurity</kwd><kwd>rat model</kwd><kwd>pathogenesis</kwd><kwd>renin-angiotensin system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Yonekawa Y., Thomas B.J., Thanos A., Todorich B., Drenser K.A., Trese M.T., Capone A. Jr. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina. 2017;37(12):2208–2225. DOI: 10.1097/IAE.0000000000001719</mixed-citation><mixed-citation xml:lang="en">Yonekawa Y., Thomas B.J., Thanos A., Todorich B., Drenser K.A., Trese M.T., Capone A. Jr. The cutting edge of retinopathy of prematurity care: expanding the boundaries of diagnosis and treatment. Retina. 2017;37(12):2208–2225. DOI: 10.1097/IAE.0000000000001719</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Катаргина Л.А., Слепова О.С., Демченко Е.Н., Осипова Н.А. Роль системного дисбаланса цитокинов в патогенезе ретинопатии недоношенных. Российская педиатрическая офтальмология. 2015;4:16–20.</mixed-citation><mixed-citation xml:lang="en">Katargina L.A., Slepova  O.S., Demchenko E.N., Osipova N.A. The role of the systemic disbalance of serum cytokine levels in pathogenesis of retinopathy of prematurity. Russian Pediatric Ophthalmology = Rossijskaya pediatricheskaya ophthlmologija. 2015;4:16–20 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner J., Jan Danser A.H., Derkx F.H., de Jong T.V., Paul M., Mullins J.J., Schalekamp M.A., Ganten D. Demonstration of renin mRNA, angiotensinogen m RNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for the intraocular renin angiotensin system. British Journal of Ophthalmology. 1996;80:159–163. PMID: 8814748</mixed-citation><mixed-citation xml:lang="en">Wagner J., Jan Danser A.H., Derkx F.H., de Jong T.V., Paul M., Mullins J.J., Schalekamp M.A., Ganten D. Demonstration of renin mRNA, angiotensinogen m RNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for the intraocular renin angiotensin system. British Journal of Ophthalmology. 1996;80:159–163. PMID: 8814748</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sarlos S., Wilkinson-Berka J.L. The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2005;46(3):1069–1077. DOI: 10.1167/iovs.04-0885. PMID: 15728567</mixed-citation><mixed-citation xml:lang="en">Sarlos S., Wilkinson-Berka J.L. The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci. 2005;46(3):1069–1077. DOI: 10.1167/iovs.04-0885. PMID: 15728567</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351:28–31. PMID: 9433426</mixed-citation><mixed-citation xml:lang="en">Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351:28–31. PMID: 9433426</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Moravski C.J., Skinner S.L., Stubbs A.J. The renin-angiotensinsystem influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. 2003;162:151–160. DOI: 10.1016/S0002-9440(10)63806-0. PMID: 12507898</mixed-citation><mixed-citation xml:lang="en">Moravski C.J., Skinner S.L., Stubbs A.J. The renin-angiotensinsystem influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am. J. Pathol. 2003;162:151–160. DOI: 10.1016/S0002-9440(10)63806-0. PMID: 12507898</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kle Gilbert R.E., Kelly D.J., Cox A.J. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia. 2000;43:1360–1367. DOI: 10.1007/s001250051539. PMID: 11126403</mixed-citation><mixed-citation xml:lang="en">Kle Gilbert R.E., Kelly D.J., Cox A.J. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia. 2000;43:1360–1367. DOI: 10.1007/s001250051539. PMID: 11126403</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lonchampt M., Pennel L., Dubault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest. Ophthalmol. Vis. Sci. 2002;42:429–432.</mixed-citation><mixed-citation xml:lang="en">Lonchampt M., Pennel L., Dubault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest. Ophthalmol. Vis. Sci. 2002;42:429–432.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Downie L.E., Hatzopoulos K.M., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Kalloniatis M., Fletcher E.L. Angiotensin type-I receptor inhibition neuroprotective to amacrine cells in a rat model of retinopathy of prematurity. J. Comp. Neur. 2010;1;518(1):41–63. DOI: 10.1002/cne.22205. PMID: 19882719</mixed-citation><mixed-citation xml:lang="en">Downie L.E., Hatzopoulos K.M., Pianta M.J., Vingrys A.J., Wilkinson-Berka J.L., Kalloniatis M., Fletcher E.L. Angiotensin type-I receptor inhibition neuroprotective to amacrine cells in a rat model of retinopathy of prematurity. J. Comp. Neur. 2010;1;518(1):41–63. DOI: 10.1002/cne.22205. PMID: 19882719</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Nath M., Chandra P., Halder N., Singh B., Deorari A.K., Kumar A., Azad R., Velpandian T. Involvement of Renin-Angiotensin System in Retinopathy of Prematurity — A Possible Target for Therapeutic Intervention. PLoS One. 2016;11(12):0168809. DOI: 10.1371</mixed-citation><mixed-citation xml:lang="en">Nath M., Chandra P., Halder N., Singh B., Deorari A.K., Kumar A., Azad R., Velpandian T. Involvement of Renin-Angiotensin System in Retinopathy of Prematurity — A Possible Target for Therapeutic Intervention. PLoS One. 2016;11(12):0168809. DOI: 10.1371</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 2003;163(3):879–887.</mixed-citation><mixed-citation xml:lang="en">Sarlos S., Rizkalla B., Moravski C.J., Cao Z., Cooper M.E., Wilkinson-Berka J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am. J. Pathol. 2003;163(3):879–887.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tamarat R., Silvestre J.S., Durie M., Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab. Invest. 2002;82:747–756.</mixed-citation><mixed-citation xml:lang="en">Tamarat R., Silvestre J.S., Durie M., Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factorand inflammation-related pathways. Lab. Invest. 2002;82:747–756.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G.D., Isner J.M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 1998;83:233–240.</mixed-citation><mixed-citation xml:lang="en">Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G.D., Isner J.M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 1998;83:233–240.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lowry O., Rozebrough N., Farr A., Randell R. Protein mеasurement with the folin phenol reagent. J. Bio. Chem. 1951;193:265–275.</mixed-citation><mixed-citation xml:lang="en">Lowry O., Rozebrough N., Farr A., Randell R. Protein mеasurement with the folin phenol reagent. J. Bio. Chem. 1951;193:265–275.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Катаргина Л.А., Хорошилова-Маслова И.П., Майбогин А.М., Панова И.Г., Осипова Н.А. Патоморфологические особенности развития экспериментальной ретинопатии недоношенных. Международный журнал прикладных и фундаментальных исследований. 2017;3(2):190–194.</mixed-citation><mixed-citation xml:lang="en">Katargina L.A., Khoroshilova-Maslova I.P., Maybogin M.A., Panova I.G., Osipova N.A. Pathomorphological features of the development of experimental retinopathy of prematurity. International Journal of Applied and Basic Research = Mezhdunarodnyj zhurnal prikladnyh i fundamental’nyh issledovanij. 2017;3(2):190–194 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Quinn G.E., Ying G.S., Bell E.F., Donohue P.K., Morrison D., Tomlinson L.A., Binenbaum G. G-ROP Study Group. Incidence and Early Course of Retinopathy of Prematurity: Secondary Analysis of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. JAMA Ophthalmol. 2018;136(12):1383–1389. DOI: 10.1001/jamaophthalmol.2018.4290</mixed-citation><mixed-citation xml:lang="en">Quinn G.E., Ying G.S., Bell E.F., Donohue P.K., Morrison D., Tomlinson L.A., Binenbaum G. G-ROP Study Group. Incidence and Early Course of Retinopathy of Prematurity: Secondary Analysis of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. JAMA Ophthalmol. 2018;136(12):1383–1389. DOI: 10.1001/jamaophthalmol.2018.4290</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J., Stahl A., Hellstrom A., Smith L.E. Current update on retinopathy of prematurity: screening and treatment. Curr. Opin. Pediatr. 2011;23(2):173–178.</mixed-citation><mixed-citation xml:lang="en">Chen J., Stahl A., Hellstrom A., Smith L.E. Current update on retinopathy of prematurity: screening and treatment. Curr. Opin. Pediatr. 2011;23(2):173–178.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
